Drug Trial News

RSS

Low dose of aspirin cuts recurrence risk in colorectal cancer with genetic mutation

A Swedish-led research team at Karolinska Institutet and Karolinska University Hospital has shown in a new randomized clinical trial that a low dose of the well-known medicine aspirin halves the risk of recurrence after surgery in patients with colon and rectal cancer with a certain type of genetic alteration in the tumor.

17 Sep 2025

Subcutaneous amivantamab plus lazertinib yields high response in EGFR-mutant lung cancer

A new analysis from the PALOMA-2 study presented today shows that subcutaneous administration of amivantamab every four weeks (Q4W), in combination with daily oral lazertinib, yields a high objective response rate in patients with previously untreated EGFR-mutated advanced non-small cell lung cancer (NSCLC).

10 Sep 2025

Combination immunotherapy prior to surgery shows encouraging results in mesothelioma

Results from an early phase clinical trial presented this week at the World Conference on Lung Cancer Meeting in Barcelona, Spain, and published in the Nature Medicine journal today [Monday, 8th September 2025] show that patients with mesothelioma - a rare cancer of the lining of the lung that may be caused by exposure to asbestos - who received a combination of two immunotherapy drugs, nivolumab and ipilimumab, before surgery had successful surgeries and encouraging early outcomes.

9 Sep 2025

City of Hope launches innovative national clinical trials model to expand access to cancer treatments

City of Hope, one of the largest and most advanced cancer research and treatment organizations in the U.S., launched an innovative national clinical trials model to expand access to emerging life-saving cancer treatments to more patients across the country.

9 Sep 2025

Tarlatamab and anti-PD-L1 therapy combination demonstrates manageable safety profile in first-line ES-SCLC

Clinical data presented today demonstrates the combination of tarlatamab with anti-PD-L1 therapy as first-line maintenance has an acceptable safety profile and resulted in unprecedented overall survival in patients with extensive-stage small cell lung cancer (ES-SCLC).

8 Sep 2025

Adjuvant chemo-immunotherapy may benefit patients with resected stage IB–IIIA NSCLC, trial suggests

Interim results from the NADIM ADJUVANT Phase III trial, led by the Spanish Lung Cancer Group (GECP), suggest that adjuvant chemo-immunotherapy may reduce the risk of recurrence in patients with completely resected stage IB–IIIA non-small cell lung cancer (NSCLC) while maintaining an acceptable safety profile.

8 Sep 2025

Ifinatamab deruxtecan may benefit patients with recurrent or progressive ES-SCLC

Patients diagnosed with recurrent or progressive extensive-stage small cell lung cancer (ES-SCLC) may benefit from treatment with ifinatamab deruxtecan (I-DXd), a B7-H3–directed antibody–drug conjugate, according to data presented today at the International Association for the Study of Lung Cancer (IASLC) 2025 World Conference on Lung Cancer (WCLC) in Barcelona, Spain.

8 Sep 2025

Aspirin therapy does not help people suffering from chronic rhinosinusitis with nasal polyps

A randomized placebo-controlled Finnish study showed that aspirin therapy does not provide significant relief for people suffering from chronic rhinosinusitis with nasal polyps who are hypersensitive to non-steroidal anti-inflammatory drugs (NSAIDs).

8 Sep 2025

Osimertinib plus chemotherapy offers overall survival advantage for patients with EGFR-mutated advanced NSCLC

Final overall survival (OS) results from the Phase III FLAURA2 trial demonstrate that first-line osimertinib plus chemotherapy significantly improves OS compared to osimertinib monotherapy in patients with EGFR-mutated (EGFRm) advanced non-small cell lung cancer (NSCLC).

8 Sep 2025

New antibody-drug conjugate iza-bren may offer promising treatment option for EGFR-mutated NSCLC patients

A novel antibody-drug conjugate (ADC), iza-bren (BL-B01D1), demonstrated encouraging safety and efficacy results in previously treated patients with EGFR-mutated non-small cell lung cancer (NSCLC), according to findings presented at the International Association for the Study of Lung Cancer (IASLC) 2025 World Conference on Lung Cancer (WCLC).

8 Sep 2025

Ivonescimab plus chemotherapy provides survival benefit for difficult-to-treat NSCLC patients

Adding ivonescimab, a first-in-class bispecific antibody targeting both PD-1 and VEGF, to chemotherapy significantly prolonged progression-free survival (PFS) compared to chemotherapy alone in patients with advanced non-small cell lung cancer (NSCLC) harboring EGFR mutations whose disease progressed on third-generation EGFR tyrosine kinase inhibitors (TKIs).

8 Sep 2025

Single penicillin injection found to be as effective as three doses for early syphilis

Researchers funded by the National Institutes of Health (NIH) have found that a single injection of the antibiotic benzathine penicillin G (BPG) successfully treated early syphilis just as well as the three-injection regimen used by many clinicians in the United States and elsewhere.

3 Sep 2025

Sacubitril/valsartan shows benefit over enalapril in heart failure caused by Chagas disease

In patients with heart failure (HF) caused by Chagas disease, sacubitril/valsartan was superior to enalapril for the composite primary endpoint, predominantly driven by a significant reduction in N-terminal pro-B-type natriuretic peptide (NT-proBNP), according to late-breaking research presented in a Hot Line session today at ESC Congress 2025.

3 Sep 2025

Evolocumab fails to reduce vein graft disease after coronary artery bypass surgery

After coronary artery bypass grafting (CABG), evolocumab did not reduce saphenous vein graft disease rates at 2 years compared with placebo, according to late-breaking research presented in a Hot Line session today at ESC Congress 2025 and simultaneously published in Lancet.

3 Sep 2025

Intravenous cangrelor provides rapid platelet inhibition in cardiogenic shock

Compared with crushed ticagrelor, intravenous cangrelor provided immediate, effective platelet inhibition, with no increase in major bleeding and lower mortality rates in patients with acute myocardial infarction and cardiogenic shock, according to late-breaking research presented in a Hot Line session today at ESC Congress 2025.

3 Sep 2025

Early aspirin discontinuation safe after complete revascularization in acute MI

Among low-risk patients with acute MI who underwent early complete revascularization and received one month of dual antiplatelet therapy (DAPT), P2Y12 inhibitor monotherapy was noninferior to continued DAPT for adverse cardiovascular and cerebrovascular events, while reducing bleeding risk.

3 Sep 2025

Azelastine nasal spray significantly reduces SARS-CoV-2 infections in clinical trial

The trial, led by Professor Robert Bals, Director of the Department of Internal Medicine V at Saarland University Medical Center and Professor of Internal Medicine at Saarland University, divided the 450 participants into two groups.

2 Sep 2025

Dormant tumor cells targeted to reduce breast cancer relapse

A first-of-its-kind, federally funded clinical trial has shown it's possible to identify breast cancer survivors who are at higher risk of their cancer coming back due to the presence of dormant cancer cells and to effectively treat these cells with repurposed, existing drugs.

2 Sep 2025

In-hospital start of dapagliflozin shows no significant short-term benefit in heart failure patients

In-hospital initiation of dapagliflozin did not significantly reduce the short-term risk of cardiovascular death or worsening heart failure (HF) in patients admitted for HF, although positive effects were seen when combining trial data, according to late-breaking research presented in a Hot Line session today at ESC Congress 2025.

1 Sep 2025

Aficamten outperforms beta-blockers in treating patients with obstructive hypertrophic cardiomyopathy

Aficamten treatment was associated with significant improvements in exercise capacity and symptoms compared with metoprolol in patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM), according to late-breaking research presented in a Hot Line session today at ESC Congress 2025 and simultaneously published in New England Journal of Medicine.

1 Sep 2025

1
2
3
4
...
1156
Next

Drug Trial News

Low dose of aspirin cuts recurrence risk in colorectal cancer with genetic mutation

Subcutaneous amivantamab plus lazertinib yields high response in EGFR-mutant lung cancer

Combination immunotherapy prior to surgery shows encouraging results in mesothelioma

City of Hope launches innovative national clinical trials model to expand access to cancer treatments

Tarlatamab and anti-PD-L1 therapy combination demonstrates manageable safety profile in first-line ES-SCLC

Adjuvant chemo-immunotherapy may benefit patients with resected stage IB–IIIA NSCLC, trial suggests

Ifinatamab deruxtecan may benefit patients with recurrent or progressive ES-SCLC

Aspirin therapy does not help people suffering from chronic rhinosinusitis with nasal polyps

Osimertinib plus chemotherapy offers overall survival advantage for patients with EGFR-mutated advanced NSCLC

New antibody-drug conjugate iza-bren may offer promising treatment option for EGFR-mutated NSCLC patients

Ivonescimab plus chemotherapy provides survival benefit for difficult-to-treat NSCLC patients

Single penicillin injection found to be as effective as three doses for early syphilis

Sacubitril/valsartan shows benefit over enalapril in heart failure caused by Chagas disease

Evolocumab fails to reduce vein graft disease after coronary artery bypass surgery

Intravenous cangrelor provides rapid platelet inhibition in cardiogenic shock

Early aspirin discontinuation safe after complete revascularization in acute MI

Azelastine nasal spray significantly reduces SARS-CoV-2 infections in clinical trial

Dormant tumor cells targeted to reduce breast cancer relapse

In-hospital start of dapagliflozin shows no significant short-term benefit in heart failure patients

Aficamten outperforms beta-blockers in treating patients with obstructive hypertrophic cardiomyopathy

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Latest News